查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844085

心臟衰竭POC 和 LOC 設備市場（按測試類型、設備類型、技術和最終用戶分類）- 全球預測，2025 年至 2032 年

Heart Failure POC & LOC Devices Market by Test Type, Device Type, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟衰竭POC 和 LOC 設備市場將成長至 7.4492 億美元，複合年成長率為 13.67%。

主要市場統計數據
基準年2024年 2.6711億美元
預計2025年 3.0192億美元
預測年份：2032年 7.4492億美元
複合年成長率（%） 13.67%

全面概述重新定義現代醫療保健中心臟衰竭的照護現場和線下診斷的技術、臨床和操作趨勢

技術進步、醫療服務模式的轉變以及日益複雜的生物學見解的融合，使照護現場和線下診斷設備成為心臟衰竭管理的前沿。本執行摘要概述了影響臨床、商業、監管和供應鏈領域中相關人員的最重要的發展。它強調了新興診斷方式、設備外形規格和付款人期望如何重塑心臟衰竭的檢測和監測時間、地點和方式，並概述了對製造商、醫療系統和投資者的影響。

在整個醫療保健領域，臨床醫生需要更快、可操作的數據來支援護理協調、分診決策和遠端監控。同時，設備製造商正在從單一分析物測試轉向連接複用平台，將生物感測器和影像處理功能整合到穿戴式裝置和桌上型裝置中。因此，產品開發週期越來越強調互通性、資料安全性和以使用者為中心的設計，以滿足急診和社區照護的需求。以下章節重點介紹轉型轉變、資費主導的供應鏈效應以及細分市場和特定區域的洞察，最後提供可行的建議，並對用於得出我們研究結果的分析方法進行清晰的解釋。

生物標記科學、感測器小型化和分散護理服務的進步如何重塑心臟衰竭患者的診斷和監測

心臟衰竭治療正在經歷變革性變革，這得益於新型生物檢測、設備微型化以及注重早期療育和縱向監測的新型護理模式的相互作用。基因組學、蛋白質組學和代謝組學檢測領域的創新正在擴大臨床醫生可用的生物標記範圍，從而能夠對心臟衰竭症候群進行更細緻的表現型分析，並識別出此前因臨床異質性而難以識別的治療靶點。同時，基於生物感測器的系統和成像平台正在使在傳統醫院環境之外進行持續或近乎即時的生理評估成為可能。

這項技術變革與不斷發展的臨床路徑相輔相成，使診斷智慧更貼近患者。穿戴式和可攜式診斷設備如今能夠提供持續的生理訊號，並與實驗室檢測相結合，創建有助於個人化治療方案調整的混合診斷方案。隨著互通性和雲原生分析技術的成熟，護理團隊可以將縱向訊號與個別檢測結果結合，從而更早發現病情進展，減少可避免的住院治療。法律規範和報銷機制也逐漸調整，鼓勵以結果為導向的部署，並強調資料完整性、臨床檢驗和病人安全。總而言之，這些發展預示著一個新時代的到來，在這個時代，診斷的準確性、分散式護理和數位化將改善心臟衰竭的管理。

評估近期美國關稅動態如何影響心臟衰竭診斷和監控設備的供應鏈彈性、採購選擇和產品設計決策

美國近期的關稅調整和貿易政策轉變，對服務於心臟衰竭照護現場和線下診療市場的製造商和經銷商的供應鏈和商業策略產生了複雜的下游影響。關稅導致的零件成本上漲，可能會對依賴專用感測器、成像模組和進口試劑的設備製造商造成特別嚴重的衝擊。因此，採購團隊被迫探索替代採購管道，與供應商協商簽訂長期契約，並加速垂直整合，以保護利潤率並確保供應的連續性。

關稅不僅影響直接成本，還會影響策略選擇，例如區域製造地、庫存政策以及優先考慮模組化和組件標準化的產品設計決策。企業正在透過跨區域多元化供應商、確定二級製造地以及重新設計設備來應對，以最大限度地減少對關稅敏感型投入的依賴。對於臨床合作夥伴和醫療系統而言，這些變更可能會改變設備採購時間表，需要製定適應性採購策略，優先考慮可行的替代方案，並加速在地採購技術的臨床檢驗。重要的是，在供應鏈轉變期間，法規遵循和品質保證仍然是不可協商的。相關人員必須在速度與嚴格的臨床和安全監督之間取得平衡，以維護病患信心和系統彈性。

透過對測試模式、設備外形規格、支援技術和護理環境進行分層細分，獲得洞察，從而優先考慮臨床檢驗和商業化途徑

基於細分市場的洞察揭示了不同的模式和用例如何推動心臟衰竭診斷領域的研究和商業化重點。依檢測類型，市場涵蓋基因組學、代謝組學和蛋白​​質組學檢測，每種檢測都各具優勢。基因組學檢測有助於遺傳風險和治療反應分層，代謝組學分析可捕捉與充血和灌注相關的動態代謝異常，蛋白質組學檢測可揭示與心肌壓力和重塑相關的蛋白質生物標記。結合這些檢測，可以建立一個多層級的診斷架構，其中分子特徵與生理監測相輔相成，從而提高診斷和預後的準確性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 在照護現場心臟衰竭診斷中採用人工智慧驅動演算法進行預測風險分層
  • 開發微流體實驗室晶片平台，實現心臟衰竭監測的連接複用生物標記檢測
  • 將穿戴式感測器數據與照護現場設備結合，以促進心臟衰竭患者的遠端系統管理
  • 基於奈米材料的生物感測器的進展提高了 LOC 系統中檢測心臟衰竭標記物的靈敏度
  • 加速新興市場創新心臟衰竭即時診斷技術核准的監管途徑
  • 設備製造商和遠端醫療提供者之間的協作生態系統，以增強心臟衰竭管理的連接性
  • 影響照護現場和實驗室晶片設備在心臟衰竭治療中的應用的商業化挑戰和成本效益分析
  • 推出一款智慧型手機整合實驗室晶片設備，可實現攜帶式、家用的心臟衰竭生物標記定量測量

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章。心臟衰竭POC 和 LOC 設備市場（按測試類型）

  • 基因組檢測
  • 代謝體學檢測
  • 蛋白質體檢測

第9章：心臟衰竭POC 和 LOC 設備市場（按設備類型）

  • 診斷設備
    • 心臟生物標記分析儀
    • 心臟影像診斷設備
    • 心電圖（ECG）
  • 穿戴式裝置
    • 體外去心房顫動
    • 心率監測器

第 10 章。心臟衰竭POC 和 LOC 設備市場（按技術）

  • 基於生物感測器的系統
  • 基於成像和電阻的平台
  • 免疫檢測
  • 基於核酸的平台

第 11 章。心臟衰竭POC 和 LOC 設備市場（按最終用戶）

  • 輔助生活醫療保健
  • 居家護理設施
  • 醫院和診所
  • 實驗室

第 12 章。心臟衰竭POC 和 LOC 設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章心臟衰竭POC 和 LOC 設備市場：按類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。心臟衰竭POC 和 LOC 設備市場（按國家/地區）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • ACON Laboratories Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Boston Scientific Corporation
    • Cipla Limited
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fukuda Denshi Co., Ltd.
    • Jant Pharmacal Corporation
    • Johari Digital India Limited by Syrma SGS
    • Koninklijke Philips NV
    • LifeSign LLC
    • LifeSync
    • Luminex Corporation by DiaSorin SpA
    • Mitsubishi Chemical Group Corporation
    • Nexus Dx, Inc
    • Nihon Kohden Corporation
    • Quidel Corporation
    • Schiller AG
    • Shenzhen EDAN Instrument Co., Ltd.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Siemens Healthineers AG
    • Spectral Diagnostics Inc.
    • Trinity Biotech PLC
Product Code: MRR-CA17E905EA91

The Heart Failure POC & LOC Devices Market is projected to grow by USD 744.92 million at a CAGR of 13.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 267.11 million
Estimated Year [2025] USD 301.92 million
Forecast Year [2032] USD 744.92 million
CAGR (%) 13.67%

An integrated overview of technological, clinical, and operational trends redefining heart failure point-of-care and line-of-care diagnostics in modern healthcare

The convergence of technological advances, shifting care delivery models, and increasingly granular biological insights has placed point-of-care and line-of-care devices at the forefront of heart failure management. This executive summary synthesizes the most consequential developments affecting stakeholders across clinical, commercial, regulatory, and supply chain domains. It articulates how emerging diagnostic modalities, device form factors, and payer expectations are reshaping where, when, and how heart failure is detected and monitored, and it frames implications for manufacturers, health systems, and investors.

Across care settings, clinicians demand faster, more actionable data to support treatment adjustments, triage decisions, and remote monitoring. Concurrently, device makers are moving from single-analyte tests toward multiplexed platforms and integrating biosensor and imaging capabilities into wearable and bench devices. As a result, product development cycles increasingly emphasize interoperability, data security, and user-centered design to meet the needs of both acute care and community-based practitioners. The following sections unpack transformative shifts, tariff-driven supply chain effects, and segmentation- and region-specific insights, concluding with pragmatic recommendations and a transparent description of analytical methods used to derive the findings.

How converging advances in biomarker science, sensor miniaturization, and decentralized care delivery are reshaping diagnostics and monitoring for heart failure patients

Heart failure care is undergoing transformative shifts driven by the interplay of novel biological testing, device miniaturization, and new models of care that prioritize early intervention and longitudinal monitoring. Innovations in genomic, proteomic, and metabolomic testing are expanding the range of biomarkers available to clinicians, enabling more nuanced phenotyping of heart failure syndromes and identifying therapeutic targets previously obscured by clinical heterogeneity. In parallel, biosensor-based systems and imaging-enhanced platforms are permitting continuous or near-real-time physiologic assessment outside traditional hospital settings.

These technological shifts are complemented by evolving clinical pathways that move diagnostic intelligence closer to the patient. Wearable devices and ambulatory diagnostic devices now provide sustained physiologic signals that, when integrated with lab-based assays, create hybrid diagnostic profiles that inform personalized titration of therapies. As interoperability and cloud-native analytics mature, care teams can synthesize longitudinal signals with discrete test results to detect decompensation earlier and reduce avoidable admissions. Regulatory frameworks and reimbursement mechanisms are adapting incrementally, incentivizing outcomes-driven deployments while emphasizing data integrity, clinical validation, and patient safety. Taken together, these developments herald a new era in which diagnostic precision, care decentralization, and digital enablement converge to improve heart failure management.

Assessing how recent United States tariff dynamics are shaping supply chain resilience, sourcing choices, and product design decisions for heart failure diagnostic and monitoring devices

Recent tariff adjustments and trade policy shifts in the United States create complex downstream effects on the supply chains and commercial strategies of manufacturers and distributors serving heart failure point-of-care and line-of-care markets. Tariff-driven increases in component costs can disproportionately affect device makers that rely on specialized sensors, imaging modules, and imported assay reagents. As a result, procurement teams face pressure to seek alternative sourcing, negotiate longer-term supplier agreements, or accelerate vertical integration to preserve margin and ensure continuity of supply.

Beyond direct cost implications, tariffs influence strategic choices such as regional manufacturing footprints, inventory policy, and product design decisions that favor modularity and component standardization. Companies are responding by diversifying suppliers across geographies, qualifying secondary manufacturing sites, and redesigning devices to minimize reliance on tariff-sensitive inputs. For clinical partners and health systems, these changes may alter device availability timelines and necessitate adaptive purchasing strategies that prioritize validated alternatives and accelerate clinical validation of locally sourced technologies. Importantly, regulatory compliance and quality assurance remain non-negotiable during supply chain shifts, and stakeholders must balance speed with rigorous clinical and safety oversight to maintain patient trust and system resilience.

Insights informed by layered segmentation of test modalities, device form factors, enabling technologies, and care settings to prioritize clinical validation and commercialization pathways

Segmentation-driven insight reveals how different modalities and use cases are steering research and commercialization priorities within the heart failure diagnostic landscape. Based on test type, the market is studied across genomic testing, metabolomic testing, and proteomic testing, each offering distinct advantages: genomic approaches help stratify inherited risk and therapy response, metabolomic profiling captures dynamic metabolic derangements linked to congestion and perfusion, and proteomic assays illuminate protein biomarkers that correlate with myocardial stress and remodeling. Together, these test types support a layered diagnostic architecture in which molecular signatures complement physiologic monitoring to refine diagnosis and prognostication.

Based on device type, the market is studied across diagnostic devices and wearable devices. Diagnostic devices are further studied across cardiac biomarker analyzers, cardiac imaging devices, and electrocardiogram (ECG) systems. Cardiac biomarker analyzers enable point-of-care quantification of peptides and enzymes critical for acute assessment, while compact imaging and impedance platforms extend structural and hemodynamic evaluation to non-traditional settings. Electrocardiogram systems remain foundational for rhythm and conduction assessment and are increasingly integrated into multimodal diagnostic suites. Wearable devices are further studied across external defibrillators and heart rate monitors, reflecting a spectrum that ranges from life-saving emergency interventions to continuous physiologic surveillance that supports early intervention.

Based on technology, the market is studied across biosensor-based systems, imaging & impedance-based platforms, immunoassays, and nucleic acid-based platforms. Biosensor-based systems drive continuous, minimally invasive monitoring; imaging and impedance technologies add structural and fluid status context; immunoassays provide rapid protein-based quantification; and nucleic acid platforms facilitate precision-level molecular diagnostics. Based on end user, the market is studied across assisted living healthcare, home care facilities, hospitals & clinics, and laboratory settings, each with unique operational constraints, staffing models, and data integration requirements. When considered together, these segmentation layers reveal where investment and clinical validation should concentrate to create interoperable, clinically actionable diagnostic pathways across care environments.

Regional adoption patterns and regulatory heterogeneity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence commercialization strategies and clinical deployment

Regional dynamics materially influence device adoption patterns, regulatory approaches, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems increasingly emphasize outpatient management and value-based initiatives that create demand for rapid, actionable diagnostics and remote monitoring solutions. This environment favors devices and platforms that integrate with electronic medical records and support care-coordination workflows, as well as those that demonstrate impact on readmissions and resource utilization.

Across Europe, Middle East & Africa, diverse regulatory landscapes and reimbursement models shape adoption heterogeneously. High-income European markets often prioritize clinical validation and interoperability standards, while resource-constrained settings focus on cost-effectiveness and robustness. As a result, manufacturers must tailor market-entry strategies to local regulatory requirements and demonstrate pragmatic benefits in both tertiary centers and community settings. In the Asia-Pacific region, rapid adoption of digital health, large population cohorts, and growing local manufacturing capacity generate opportunities for scalable deployments of biosensor-enabled wearables and compact diagnostic devices. Strategic partnerships with regional distributors and clinical networks accelerate validation and uptake, while localization efforts in design and service support enhance user adoption. Across all regions, data governance, privacy compliance, and supply chain stability remain critical considerations for successful commercialization.

Analyzing competitive forces where incumbent manufacturers, diagnostics innovators, and tech-enabled entrants converge to form partnerships and differentiate through clinical evidence and service models

Competitive dynamics in the heart failure point-of-care and line-of-care space reflect a mix of established medical device firms, specialized diagnostics developers, and technology-focused entrants that blend hardware, assays, and analytics. Established device manufacturers leverage legacy relationships with health systems and supply chain scale to distribute diagnostic devices and integrated platforms, while smaller innovators focus on niche biologic assays, novel biosensors, and software-enabled monitoring solutions that prioritize user experience and connectivity.

Collaborations between device makers and clinical research networks are increasingly common because co-development helps accelerate real-world validation and payer engagement. Strategic alliances, licensing arrangements, and OEM partnerships enable rapid scaling while preserving clinical credibility. Additionally, the integration of analytics and cloud services creates new value propositions around predictive maintenance, population health management, and remote patient management. As a result, companies that can demonstrate clinical utility, regulatory compliance, and secure data interoperability gain a competitive advantage. Supply chain adaptability, modular product architectures, and the ability to offer bundled hardware-plus-service models further distinguish market leaders from niche players. Ultimately, the competitive landscape rewards organizations that align rigorous clinical evidence generation with nimble commercial execution and robust post-market support.

Practical strategic actions for manufacturers and health system leaders to accelerate adoption, strengthen supply resilience, and align evidence generation with payer priorities

Industry leaders should prioritize a set of actionable measures that accelerate clinical adoption and safeguard commercial resilience. First, align product development with clinically meaningful endpoints and pragmatic trial designs that reflect real-world workflows and demonstrate outcomes that matter to payers and providers. This focus reduces time-to-adoption friction and strengthens reimbursement discussions. Second, invest in supply chain diversification and component standardization to reduce exposure to tariff shocks and geopolitical disruption. Dual-sourcing critical components and qualifying alternate manufacturing sites will enhance continuity and enable more predictable delivery schedules.

Third, design devices and software with interoperability and cybersecurity by default, ensuring seamless integration with electronic health records and remote monitoring platforms while protecting patient data. Fourth, pursue strategic partnerships with care networks and home health providers to validate care models that leverage diagnostic and wearable combinations, enabling smoother commercialization pathways. Fifth, adopt flexible commercial models that combine device sales with subscription-based analytics and service agreements to create recurring revenue and deeper system integration. Finally, maintain an active engagement with regulators and payers to shape pragmatic evidence requirements and to accelerate pathways for reimbursement that reflect real-world value.

Transparent description of the research approach integrating primary interviews, literature synthesis, and scenario analysis to derive actionable insights without relying on numerical market forecasts

This analysis synthesizes primary interviews with clinical leaders, device manufacturers, supply chain experts, and regulatory advisors, complemented by a systematic review of peer-reviewed literature and public regulatory guidance relevant to heart failure diagnostics and monitoring. Primary qualitative input focused on clinical workflows, device usability, sourcing strategies, and commercialization hurdles. Secondary sources provided technical context on biosensor technologies, assay performance characteristics, and recent policy shifts influencing trade and reimbursement. The methodology prioritized triangulation to validate emergent themes across multiple data sources and to surface actionable insights rather than raw market estimates.

Analytical steps included mapping the diagnostic and device ecosystem by test type, device form factor, enabling technology, and end-user environment to reveal where clinical need and technical feasibility align. Scenario analysis explored supply chain responses to tariff and trade policy changes, emphasizing operational strategies that preserve quality and continuity. Evidence synthesis highlighted recurring barriers to adoption-such as integration burden, clinical validation gaps, and reimbursement uncertainty-and identified levers for acceleration including strategic partnerships, localized manufacturing, and flexible commercial models. Wherever applicable, findings were cross-validated with domain experts to ensure relevance and practical applicability for decision-makers.

Synthesis of how innovation, clinical validation, and resilient commercialization strategies must converge to turn diagnostic and monitoring advances into tangible improvements in heart failure care

The landscape of heart failure point-of-care and line-of-care devices is marked by rapid technical innovation, evolving care models, and heightened sensitivity to supply chain and policy dynamics. New molecular tests and biosensor-enabled monitoring are expanding diagnostic possibilities, while modular device architectures and data-driven services are redefining commercial value. Concurrent pressures from trade policy and tariff changes underscore the need for resilient sourcing and adaptive manufacturing strategies that do not compromise clinical quality or regulatory compliance.

Looking ahead, stakeholders who integrate rigorous clinical validation with pragmatic commercialization approaches and robust supply chain planning will be best positioned to capture clinical trust and operational scale. Cross-sector collaboration among manufacturers, care providers, payers, and regulators remains essential to translate technological promise into sustained improvements in patient outcomes. By focusing on interoperability, evidence generation tied to meaningful clinical endpoints, and flexible deployment models suited to regional contexts, organizations can accelerate the adoption of diagnostic and wearable solutions that meaningfully improve heart failure management across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven algorithms in point-of-care heart failure diagnostics for predictive risk stratification
  • 5.2. Development of microfluidic lab-on-chip platforms enabling multiplexed biomarker detection for heart failure monitoring
  • 5.3. Integration of wearable sensor data with point-of-care devices to facilitate remote heart failure patient management
  • 5.4. Advancements in nanomaterial-based biosensors for increasing sensitivity of heart failure marker detection in LOC systems
  • 5.5. Regulatory pathways accelerating the approval of innovative heart failure point-of-care diagnostic technologies in emerging markets
  • 5.6. Collaborative ecosystem between device manufacturers and telehealth providers enhancing connectivity for heart failure management
  • 5.7. Commercialization challenges and cost-effectiveness analyses influencing adoption of point-of-care and lab-on-chip devices in heart failure care
  • 5.8. Emergence of smartphone-integrated lab-on-chip devices offering portable heart failure biomarker quantification at-home use

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure POC & LOC Devices Market, by Test Type

  • 8.1. Genomic Testing
  • 8.2. Metabolomic Testing
  • 8.3. Proteomic Testing

9. Heart Failure POC & LOC Devices Market, by Device Type

  • 9.1. Diagnostic Devices
    • 9.1.1. Cardiac Biomarker Analyzers
    • 9.1.2. Cardiac Imaging Devices
    • 9.1.3. Electrocardiogram (ECG)
  • 9.2. Wearable Devices
    • 9.2.1. External Defibrillator
    • 9.2.2. Heart Rate Monitors

10. Heart Failure POC & LOC Devices Market, by Technology

  • 10.1. Biosensor-based systems
  • 10.2. Imaging & impedance-based platforms
  • 10.3. Immunoassays
  • 10.4. Nucleic acid-based platforms

11. Heart Failure POC & LOC Devices Market, by End User

  • 11.1. Assisted Living Healthcare
  • 11.2. Home Care Facilities
  • 11.3. Hospitals & Clinics
  • 11.4. Laboratory

12. Heart Failure POC & LOC Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Heart Failure POC & LOC Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Heart Failure POC & LOC Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. ACON Laboratories Inc.
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. Bio-Rad Laboratories, Inc.
    • 15.3.5. bioMerieux S.A.
    • 15.3.6. Boston Scientific Corporation
    • 15.3.7. Cipla Limited
    • 15.3.8. Danaher Corporation
    • 15.3.9. F. Hoffmann-La Roche Ltd.
    • 15.3.10. Fukuda Denshi Co., Ltd.
    • 15.3.11. Jant Pharmacal Corporation
    • 15.3.12. Johari Digital India Limited by Syrma SGS
    • 15.3.13. Koninklijke Philips N.V.
    • 15.3.14. LifeSign LLC
    • 15.3.15. LifeSync
    • 15.3.16. Luminex Corporation by DiaSorin S.p.A.
    • 15.3.17. Mitsubishi Chemical Group Corporation
    • 15.3.18. Nexus Dx, Inc
    • 15.3.19. Nihon Kohden Corporation
    • 15.3.20. Quidel Corporation
    • 15.3.21. Schiller AG
    • 15.3.22. Shenzhen EDAN Instrument Co., Ltd.
    • 15.3.23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Spectral Diagnostics Inc.
    • 15.3.26. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEART FAILURE POC & LOC DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 262. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 263. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 264. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 265. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MI